- Trials with a EudraCT protocol (26)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
26 result(s) found for: Bacterial Infections AND Pneumonia AND Lobar Pneumonia.
Displaying page 1 of 2.
EudraCT Number: 2012-002203-18 | Sponsor Protocol Number: P903-31 | Start Date*: 2012-07-18 | ||||||||||||||||||||||||||
Sponsor Name:Cerexa, Inc. (subsidary of Forest Laboratories) | ||||||||||||||||||||||||||||
Full Title: A Multicenter, Randomized, Observer-Blinded, Active-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Ceftaroline Versus Ceftriaxone in Pediatric Subjects With... | ||||||||||||||||||||||||||||
Medical condition: Community-acquired Bacterial Pneumonia | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA HU (Completed) GR (Completed) ES (Completed) PL (Completed) BG (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2009-016069-27 | Sponsor Protocol Number: DORIPED3003 | Start Date*: 2010-05-28 | |||||||||||
Sponsor Name:Janssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium | |||||||||||||
Full Title: A Prospective, Randomized, Double-Blind, Multicenter Study to Establish the Safety and Tolerability of Doripenem Compared With Cefepime in Hospitalized Children With Bacterial Pneumonia | |||||||||||||
Medical condition: Bacterial Pneumonia | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: LT (Prematurely Ended) LV (Prematurely Ended) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2010-021574-11 | Sponsor Protocol Number: 32729463CAP2001 | Start Date*: 2011-01-24 | |||||||||||
Sponsor Name:Furiex Pharmaceuticals, Inc | |||||||||||||
Full Title: A Randomized, Controlled, Double-Blind, Multicenter, Phase 2 Study of the Safety/Tolerability and Efficacy of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospita... | |||||||||||||
Medical condition: Community-Acquired Bacterial Pneumonia (CABP) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) HU (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-004650-25 | Sponsor Protocol Number: 110521 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, open, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3-dose pr... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants against Streptococcus pneumonia, diphtheria, tetanus, pertussis, hepatitis B, Haemophilus influenzae type b and polio diseases) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000826-23 | Sponsor Protocol Number: 113199 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for booster immunization of healthy children previously primed with 3 doses of pneumococcal conjugate vaccine [Pn-Pn group] or a two-dose catch-up immunization in unprimed child... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000162-38 | Sponsor Protocol Number: 113151 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III open-label study to assess the safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine when co-administered with GSK Biologicals’ Infanr... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for three-dose primary vaccination against Streptococcus pneumoniae in healthy infants between 6 to 12 weeks of age at the time of the first vaccination) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003711-39 | Sponsor Protocol Number: 113166 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, open, single centre study to assess the safety, reac-togenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vaccine (GSK 102... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for booster immunization of healthy children previously primed with 3 doses of pneumococcal conjugate vaccine or a two-dose catch-up immunization in unprimed children in the sec... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2012-000819-82 | Sponsor Protocol Number: 113266 | Start Date*: 2015-05-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, multi-centre, open study to assess antibody persistence after completion of the 3-dose primary vaccination course with GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjuga... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (a single-dose booster vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases in healthy children ... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001506-34 | Sponsor Protocol Number: 112933 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, controlled, single-blind study to assess the reactogenicity, safety and immunogenicity of a booster dose of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine ... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Booster vaccination at 12-18 months of age against Streptococcus pneumoniae and Haemophilus influenzae type b in healthy children primed with the same study vaccines in study 10... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001511-12 | Sponsor Protocol Number: 109861 | Start Date*: 2015-06-10 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, single group, open study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine in Taiwan when co-admini... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, hepatitis B, polio, Haemophilus influenzae type b diseases and a two dose primar... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-001505-14 | Sponsor Protocol Number: 110808 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, controlled, single-blind study to evaluate the non-inferiority of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate vaccine compared to the 7-valent pneumococca... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae and Haemophilus influenzae t... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-000101-12 | Sponsor Protocol Number: 111654 | Start Date*: 2015-05-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, multi-centre, double-blind, randomised study to assess the non-inferiority of a commercial lot of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate (10Pn-PD-DiT) vacc... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three-dose primary vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and Haemophilus influenzae type b diseases, either a two-dose or t... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-004644-22 | Sponsor Protocol Number: 111188 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, single-blind, controlled study to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine as a 3... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 10 weeks of age at the time of the first vaccination against Streptococcus pneumoniae, diphtheria, tetanus, pertus... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2006-000557-21 | Sponsor Protocol Number: 107007 | Start Date*: 2015-06-17 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase IIIb randomized, double-blind, controlled study to assess the safety, reactogenicity and immunogenicity of GlaxoSmithKline (GSK) Biologicals’ 10-valent pneumococcal conjugate vaccine compar... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Three dose primary vaccination of healthy infants between 6 to 12 weeks of age at the time of the first vaccination against Streptococcus pneumoniae) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2013-003479-36 | Sponsor Protocol Number: 115992 | Start Date*: 2015-05-20 | ||||||||||||||||||||||||||
Sponsor Name: GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, controlled, partially-blind study to assess the reactogenicity, safety and immunogenicity of GSK Biologicals' 10-valent pneumococcal polysaccharide and non-typeable Haemophilus influen... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (Two-dose primary vaccination of healthy infants 6-12 weeks of age at the time of first vaccination against S. pneumoniae and H. influenzae according to a 2 months interval sched... | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-003710-16 | Sponsor Protocol Number: 112640 | Start Date*: 2015-05-13 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, randomized, open, controlled study in healthy Japanese children to assess the immunogenicity, safety and reactogenicity of GlaxoSmithKline Biologicals’ 10-valent pneumococcal conjugate... | ||||||||||||||||||||||||||||
Medical condition: Healthy volunteers (for active immunization against invasive disease and acute otitis media caused by Streptococcus pneumoniae in infants and children from 6 weeks up to 2 years of age) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2011-006013-34 | Sponsor Protocol Number: 115884 | Start Date*: 2013-01-11 | ||||||||||||||||||||||||||
Sponsor Name:GlaxoSmithKline Biologicals | ||||||||||||||||||||||||||||
Full Title: A phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of GSK Biologicals' 10-valent pneumococcal conjugate vaccine when administered to childr... | ||||||||||||||||||||||||||||
Medical condition: Active immunization against disease caused by Streptococcus pneumoniae in children 2-17 years of age who are at increased risk of pneumococcal infection. | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |||||||||||||||||||||||||||
Trial protocol: Outside EU/EEA PL (Completed) | ||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2014-004039-37 | Sponsor Protocol Number: CE01-203 | Start Date*: 2014-10-10 |
Sponsor Name:Cempra Pharmaceuticals, Inc. | ||
Full Title: A Phase 2/3, Randomised, Partly blinded (blinded investigator), Multi-center, Comparative Study to Determine the Safety and activity of Solithromycin (Intravenous and oral) in paediatric patients ... | ||
Medical condition: suspected or confirmed community acquired bacterial pneuumonia (CABP) | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA GB (Completed) HU (Completed) ES (Temporarily Halted) | ||
Trial results: View results |
EudraCT Number: 2009-016579-31 | Sponsor Protocol Number: OVG2008/6 | Start Date*: 2010-01-14 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Sponsor Name:University of Oxford | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Full Title: An open label randomised controlled study to evaluate the induction of immune memory following infant vaccination with a glyco-conjugate Neisseria meningitidis serogroup C vaccine and to assess the... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Medical condition: Active immunisation of children for the prevention of invasive diseases caused by Neisseria meningitidis serogroup C, Streptococcus pneumoniae, diphtheria, tetanus, pertussis, poliomyelitis and inv... | |||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial protocol: GB (Completed) | |||||||||||||||||||||||||||||||||||||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-022303-22 | Sponsor Protocol Number: B1851047 | Start Date*: 2011-06-22 | |||||||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | |||||||||||||||||||||||
Full Title: A PHASE 4, RANDOMIZED, OPEN-LABEL TRIAL TO ASSESS THE IMPACT OF PROPHYLACTIC ANTIPYRETIC MEDICATION ON THE IMMUNOGENICITY OF 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE GIVEN WITH ROUTINE PEDIATRIC VA... | |||||||||||||||||||||||
Medical condition: Pneumonia and ear infections caused by S pneumoniae. | |||||||||||||||||||||||
|
|||||||||||||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||||||||||||
Trial protocol: PL (Completed) | |||||||||||||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.